KEY DETAILS
This week's roundup covers GLP-1 news from Novo Nordisk, Eli Lilly, Bupa, and UKHSA.
UK presenter Alison Hammond says she lost 11 stone without Ozempic or other weight-loss drugs.
Some investors are asking whether Eli Lilly will split its stock. The company has not announced a split.
One writer described how extreme thinness dulled her pleasure and usual optimism.
A genetic study found men with gene variants that raise GLP-1 receptor activity were 7% more likely to have male-pattern baldness. It does not show the drugs cause it.
Alison Hammond, who has lost 11 stone, says she did it without Ozempic or any other weight-loss drug, and her story was one part of a week of GLP-1 news that reached well beyond celebrities. Some investors asked whether Eli Lilly will split its stock, researchers published new data on a side effect rarely mentioned alongside nausea, and one writer described what significant weight loss actually felt like from the inside. That range says something about how differently one medication can be discussed.
This week's roundup pulls together voices from Novo Nordisk and Eli Lilly, the two companies making the drugs at the center of this boom, alongside Bupa and the UK Health Security Agency. The stories below reflect that spread, from a presenter's personal account to a scientific study on side effects.
Alison Hammond has been clear about how she lost 11 stone: she says she did it without Ozempic or any other weight-loss drug. She has said she was "one point away from being diabetic," and she credits regular exercise with personal trainers, including Pilates, boxing, circuit training and strength training. She has pushed back on claims that a drug was behind the change. Her account is a reminder not to assume how anyone lost weight.
Some investors are asking whether Eli Lilly will split its stock, and are looking back at how its shares behaved after past splits. Lilly has not announced a split. A stock split does not change the value of the company, but it does lower the price per share, which can make the stock more accessible to smaller investors and sometimes shifts trading patterns. History does not guarantee a repeat performance, but it gives investors a rough guide for what to expect. For readers who hold Lilly stock or are simply watching the company's fortunes, the split talk is a reminder that the business behind these drugs is also being read by markets, not only by doctors and patients.
Not every story this week was about progress. One writer described how getting significantly thinner left her flatter emotionally, not lighter, saying it dulled her pleasure and took away her usual optimism. Her account complicates the idea that reaching a lower weight automatically brings relief or happiness. It suggests some people experience unwanted effects in mood and outlook, not only on a scale. That points to a willingness to talk about weight loss in more complicated terms than usual.
A new genetic study from NYU Langone added a more clinical note. It found that men with gene variants that raise GLP-1 receptor activity were 7% more likely to have male-pattern baldness. The study did not look at men taking the drugs, and it does not show that the drugs cause hair loss. Still, it gives men considering these drugs one more factor to raise with their doctor before starting treatment.
Taken together, this week's stories show that the conversation around GLP-1 drugs keeps expanding into new territory, from financial markets to emotional side effects. If you are on one of these medications, pay attention to both what changes on the outside and what changes in how you feel day to day. Personal accounts and the new hair loss data are useful reminders that these drugs come with a full range of effects, not just the ones tracked on a scale. If something feels off, whether that is your mood or something physical like hair loss, it is worth raising with your doctor.
Read this on GLP-1 Nation: https://glp1nation.com/edition/39
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.